drugset
drugset / Trial / NCT05043285

The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.

NCT05043285 ↗

Phase 1/2 Unknown 300 enrolled Sinocelltech Ltd.
RandomizedParallel-groupTriple-blindPrevention

Summary

The objective of this study is to evaluate the safety, tolerability, and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with inactivated COVID-19 vaccine.

Timeline

Start
2021-12-22
Primary completion
2022-06-01
Completion
2023-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SCTV01C Vaccine 20 ug Intramuscular
Subject SCTV01C Vaccine 40 ug Intramuscular

Indications

COVID-19